Last Updated : April 29, 2024
The latest CADTH Reimbursement Review reports are posted to this page. CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.
| Brand Name | Generic Name | Therapeutic Area Sort descending | Recommendation Type | Project Status | Date Submission Received | Date Recommendation Issued |
|---|---|---|---|---|---|---|
| Abilify Maintena | Aripiprazole | Schizophrenia | List with criteria/condition | Complete | ||
| Invega | Paliperidone | Schizophrenia | Do not list | Complete | ||
| Abilify | Aripiprazole | Schizophrenia | Do not list | Complete | ||
| Vraylar | cariprazine | Schizophrenia | Active | |||
| Invega Sustenna | Paliperidone palmitate | Schizophrenia | Do not list | Complete | ||
| Zeldox | Ziprasidone hydrochloride | Schizophrenia and related psychotic disorders | List with clinical criteria and/or conditions | Complete | ||
| Abilify | Aripiprazole | Schizophrenia and related psychotic disorders | List with clinical criteria and/or conditions | Complete | ||
| Perseris | risperidone | Schizophrenia, adults | Reimburse with clinical criteria and/or conditions | Complete | ||
| TBC | risperidone | Schizophrenia, adults | Suspended | |||
| Dymista | Azelastine HCl and fluticasone propionate | Seasonal allergic rhinitis | Do not list | Complete |
Last Updated : April 29, 2024